Rezum reduces lower urinary tract symptoms in men with BPH
"If you look at men who had sexual dysfunction at the beginning of the study, compared to men that had good sexual function at the beginning of a study, both groups of men have equal response to improvement in their lower urinary tract symptoms,” says Kevin T. McVary, MD, FACS.
In this video, Kevin McVary, MD, FACS, discusses the background and findings of the study, “Preservation of sexual function 5-years after water vapor thermal therapy for benign prostatic hyperplasia,” presented recently at the 2021 American Urological Association Annual Meeting. McVary is a professor of urology and director of the Center for Male Health at Loyola University Medical Center, Maywood, Illinois.
Academic, private practice urologists collaborate to change BPH reimbursement
April 1st 2024"We really aimed to affect 3 different contraindications and instead achieved retirement of the entire policy, which, we think, really opens up this wonderful technology to literally hundreds of thousands more patients across the country," says Arpeet Shah, MD.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
